Lilly’s rheumatoid arthritis drug cuts COVID-19 deaths in trial, data shows – Reuters
Eli Lilly and Co said on Thursday fewer deaths were reported among COVID-19 patients taking a combination of its rheumatoid arthritis drug and Gilead Sciences Inc’s remdesivir in a clinical trial, compared to only remdesivir.
